10-K: InMed Pharmaceuticals Inc. Files 10-K, Details Pipeline Progress and Financials

InMed Pharmaceuticals Inc. releases its annual report, highlighting advancements in its drug development programs and providing a financial overview for the fiscal year ended June 30, 2024.

Summary

• InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing small molecule drug candidates targeting the endocannabinoid system.
• The company's pipeline includes programs for Alzheimer's disease (INM-901), dry age-related macular degeneration (INM-089), and Epidermolysis Bullosa (INM-755).
• InMed's subsidiary, BayMedica, specializes in producing and selling rare cannabinoids for the health and wellness sector.
• BayMedica's sales reached approximately $4.6 million for the fiscal year ended June 30, 2024.
• The company is actively seeking strategic partnerships for its INM-755 program in EB and other itch-related skin conditions.
• InMed is developing proprietary manufacturing approaches, including IntegraSyn, to produce high-quality cannabinoids.
• The company has a total of thirteen patent families covering various areas including novel methods for treating diseases and manufacturing processes for cannabinoids.
• As of September 20, 2024, InMed had 13 full-time employees and utilizes several consultants.
• The company has incurred an accumulated deficit of approximately $109.1 million as of June 30, 2024.
• InMed's net loss for the fiscal year ended June 30, 2024 was approximately $7.7 million.
• The company's cash, cash equivalents, and short-term investments totaled approximately $6.6 million as of June 30, 2024.
• InMed has received a delisting notice from Nasdaq due to non-compliance with the minimum bid price rule and has requested a hearing to appeal the decision.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the company's drug pipeline and manufacturing capabilities, the financial losses, delisting notice, and going concern issues raise significant concerns. The sentiment is therefore cautiously negative.

Positives

• InMed has a robust pipeline of drug development candidates, including two preclinical programs targeting Alzheimers and ocular diseases, as well as a completed Phase 2 study in dermatology.
• The company has an experienced executive team and board of directors with proven track records in the pharmaceutical industry.
• InMed has multiple manufacturing approaches, providing a competitive advantage to utilize the most cost-efficient methodology.
• BayMedica has an early-mover status as a B2B supplier of rare cannabinoids to the health and wellness sector.
• The company has a diverse portfolio of patent applications covering a spectrum of commercial opportunities.
• Preclinical studies indicate that INM-901 may target multiple biological pathways.
• INM-901 is a small molecule compound that can easily cross the blood-brain barrier.
• INM-089 has demonstrated neuroprotection of photoreceptors and preservation of retinal function in preclinical studies.
• INM-755 cream showed a positive indication of enhanced anti-itch activity in a Phase 2 clinical trial.

Negatives

• InMed has incurred significant losses since its inception and anticipates incurring losses in the future.
• The company has limited commercial revenue and may never become profitable.
• InMed is dependent on key personnel, and the loss of any of them could harm the business.
• The company's securities may be delisted from Nasdaq due to non-compliance with the minimum bid price rule.
• The company's insurance may be insufficient to cover losses that may occur as a result of its operations.
• The market prices for the company's common shares are volatile and are anticipated to fluctuate in the near term.
• Raising additional capital may cause dilution to existing shareholders.
• The company has identified a material weakness in its internal control over financial reporting.
• The company's operating losses have raised substantial doubt regarding its ability to continue as a going concern.

Risks

• The company's prospects depend on the success of its Product Candidates, which are in the early stages of development with a statistically high probability of failure.
• Clinical trials of the company's Product Candidates may fail to demonstrate safety and efficacy.
• The company may fail to capitalize on other Product Candidates or other indications for its Product Candidates that may be more profitable.
• The company's Product Candidates contain compounds that may be classified as controlled substances, which may restrict their development or commercialization.
• Any actual or threatened delisting of the company's securities by Nasdaq could have a material and adverse effect on its business.
• Research restrictions, product shipment delays or prohibitions could have a material adverse effect on the company's business.
• The company's relationships with customers and third-party payors are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations.
• The company's insurance may be insufficient to cover losses that may occur as a result of its operations.
• The company may be subject to changes in laws, regulations and guidelines which are detrimental to its business.
• The company's failure to protect its information technology infrastructure against cyber-based attacks could significantly disrupt its operations.
• The company's failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties.
• The company's success is largely dependent upon its patents, proprietary technology, and other intellectual property.
• The company may become involved in lawsuits to protect or enforce its intellectual property, which could be expensive and time-consuming.
• The company relies heavily on contract manufacturers over whom it has limited control.
• The company's existing collaboration agreements and any that it may enter into in the future may not be successful.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the research and development of, and clinical trials for, its Product Candidates. The company also expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions.

Management Comments

• Our management team believes that the combined manufacturing technologies from InMed and BayMedica provide us with a competitive advantage to utilize the most cost-efficient methodology.
• Our management team believes that the combined manufacturing technologies from InMed and BayMedica provide us with a competitive advantage to utilize the most cost-efficient methodology (i.e. chemical synthesis, biosynthesis and IntegraSyn) for the development and commercialization of new Products and Product Candidates to a wide spectrum of market opportunities.

Industry Context

The document highlights InMed's focus on developing novel cannabinoid-based therapeutics, which aligns with the growing interest in the therapeutic potential of cannabinoids. The company's efforts to develop cost-effective manufacturing processes also reflect a broader industry trend towards optimizing production methods for these compounds.

Comparison to Industry Standards

• The company's focus on small molecule drug candidates is consistent with industry trends in pharmaceutical development, where small molecules are often preferred for their ease of manufacturing and oral bioavailability.
• The company's approach to targeting the endocannabinoid system is aligned with the growing interest in this pathway for treating various diseases, including neurodegenerative and inflammatory conditions.
• The company's development of proprietary manufacturing approaches, such as IntegraSyn, is similar to other companies seeking to establish a competitive advantage in the production of cannabinoids.
• The company's pipeline includes programs for Alzheimer's disease, dry age-related macular degeneration, and Epidermolysis Bullosa, which are all areas of high unmet medical need, similar to other companies in the pharmaceutical industry.
• The company's reliance on contract manufacturers is a common practice in the pharmaceutical industry, particularly for smaller companies that do not have their own manufacturing facilities.
• The company's financial results, including its net loss and accumulated deficit, are not uncommon for early-stage pharmaceutical companies that are investing heavily in research and development.
• The company's efforts to secure intellectual property protection through patents are consistent with industry standards for protecting novel drug candidates and manufacturing processes.
• The company's focus on both pharmaceutical drug development and the commercialization of rare cannabinoids in the health and wellness sector is a unique approach that may provide diversification and revenue opportunities.

Management Changes

Legal Proceedings

• The company is subject to various legal proceedings, claims and administrative proceedings that arise in the ordinary course of its business activities.
• As of the date of this report, the company does not believe it is party to any claim, proceeding or litigation the outcome of which, if determined adversely to the company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business.
• The company is not involved in any material pending legal or governmental proceedings.

Related Party Transactions

• During the years ended June 30, 2024 and 2023, Norton Rose Fulbright Canada LLP, where a director of the company is a partner, rendered legal services in the amount of $226,793 and $634,208, respectively, to the company.

Stakeholder Impact

• Shareholders may experience volatility in the share price due to the company's financial condition and delisting notice.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers of BayMedica may be impacted by changes in the company's operations and supply chain.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.
• Strategic partners may be hesitant to collaborate with the company due to its financial challenges and delisting notice.

Next Steps

• The company plans to assess long-term (7-month dosing) study in 5xFAD mice (on-going) for INM-901.
• The company plans to execute study in PS19 Tau model for INM-901.
• The company plans to continue Chemistry/Manufacturing/Controls (CMC) activities for drug substance and drug product for INM-901.
• The company plans to continue studies of receptor interactions (MoA) and Distribution, Metabolism, Pharmacokinetics (DMPK) for INM-901.
• The company plans to execute IND enabling toxicology studies for INM-901.
• The company plans to continue CMC activities for drug substance and drug product for INM-089.
• The company plans to continue studies of receptor interactions (MoA) and DMPK for INM-089.
• The company plans to conduct GLP studies for INM-089.
• The company is seeking R&D and commercial partnership opportunities for INM-755 cream.
• The company will continue to evaluate opportunities for potential structured supply arrangements and collaborations for the BayMedica commercial business.

Key Dates

Keywords

Pharmaceuticals, Cannabinoids, Drug Development, Alzheimer's Disease, Macular Degeneration, Epidermolysis Bullosa, Clinical Trials, Intellectual Property, Manufacturing, Biotechnology, Rare Cannabinoids, Health and Wellness